An observational study in Rare Diseases, Fabry Disease and Fabry Disease, Cardiac Variant, sponsored by Wuerzburg University Hospital. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-07.
Sponsored by Wuerzburg University Hospital · Observational
This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.
Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Natural history of Fabry disease has proven poor survival to ages >50 years outlining the importance to evaluate cardiac symptoms and outcomes of patients with Fabry disease.
This study is a prospective cohort study and observes patients since 2001. Through this long-term experience and the relative high number of patients this study is suggested to help estimating the risk of cardiac arrhythmias and sudden cardiac death (SCD) as well as death or heart transplantation due to terminal heart failure.
All patients in treatment in the Fabry Center Wuerzburg (FAZiT) are included in this study if informed consent is provided.
208 studies on the registry are indexed under Rare Diseases; 112 are open to participants now.
This study's planned enrollment of 650 is above the median of 200 across 127 observational studies indexed under Rare Diseases.
Browse Rare Diseases studies →Wuerzburg University Hospital is the lead sponsor of 98 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population includes every patient with Fabry disease who is seen in the FAZiT Wuerzburg. No limitations are made.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cardiac death
Patients sustaining cardiac death
Time frame: From date of inclusion until the date of first documented event, up to the year 2032
Heart transplantation
On the basis of severe cardiac damage heart transplantation is needed
Time frame: From date of inclusion until the date of first documented event, up to the year 2032
Malign Arrhythmias
Patients suffering any malign arrhythmias
Time frame: From date of inclusion until the date of death, up to the year 2032
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wuerzburg University Hospital